<DOC>
	<DOCNO>NCT01661140</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind study compare safety efficacy taper methotrexate ( MTX ) versus maintain MTX dosage patient severe active rheumatoid arthritis inadequate response disease-modifying antirheumatic drug ( DMARDs ) initiate treatment tocilizumab . Participants receive tocilizumab 8 mg/kg intravenously every 4 week MTX orally weekly throughout study . At Week 24 , participant achieve good/moderate EULAR response randomize receive MTX Tapering arm MTX Maintenance arm . Up Week 56 participant receive either taper stable dose MTX combination tocilizumab . From Week 56 Week 72 participant receive tocilizumab monotherapy .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Combination With Methotrexate Patients With Severe Active Rheumatoid Arthritis , Comparing Tapering Versus Maintaining Methotrexate Dosage</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active severe rheumatoid arthritis ( DAS28 &gt; 5.1 ) accord European League Rheumatism ( EULAR ) /American College Rheumatology ( ACR ) criteria Inadequate response trial 2 DMARDs , include methotrexate , trial define 6 month 2 month standard dose ; previous treatment biologic agent tumor necrosis factor ( TNF ) inhibitor Oral corticosteroid must stable dose &lt; /= 10 mg/day prednisolone equivalent least 25 28 day prior start treatment ( Day 1 ) Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization Rheumatic autoimmune disease rheumatoid arthritis Functional class IV define ACR Classification Functional Status RA Prior history current inflammatory joint disease RA Previous treatment tocilizumab Previous treatment biologic drug ( e.g . TNF inhibitor ) use treatment RA Intraarticular parenteral corticosteroid within 6 week prior enrollment Inadequate liver , bone marrow hepatic function Positive hepatitis B , hepatitis C HIV infection Pregnant breastfeed woman Females childbearing potential use reliable mean contraception History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Active current history recurrent bacterial , viral , fungal , mycobacterial infection History , currently active , primary secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>